Full year 2024 product sales
The following table provides the top 20 product net sales from continuing operations in 2024, as well as the change compared with 2023:
| Brands | Net Sales (USD m) | % change (USD) | % change (cc1) | Brand classification by therapeutic area or established brands |
|---|---|---|---|---|
| Entresto | 7,822 | 30 | 31 | Cardiovascular, renal and metabolic |
| Cosentyx | 6,141 | 23 | 25 | Immunology |
| Kesimpta | 3,224 | 49 | 49 | Neuroscience |
| Kisqali | 3,033 | 46 | 49 | Oncology |
| Promacta/Revolade | 2,216 | -2 | -1 | Oncology |
| Tafinlar + Mekinist | 2,058 | 7 | 9 | Oncology |
| Jakavi | 1,936 | 13 | 15 | Oncology |
| Tasigna | 1,671 | -10 | -8 | Oncology |
| Xolair2 | 1,643 | 12 | 15 | Immunology |
| Ilaris | 1,509 | 11 | 14 | Immunology |
| Pluvicto | 1,392 | 42 | 42 | Oncology |
| Sandostatin Group | 1,279 | -3 | -1 | Established brands |
| Zolgensma | 1,214 | 0 | 2 | Neuroscience |
| Lucentis | 1,044 | -29 | -28 | Established brands |
| Leqvio | 754 | 112 | 114 | Cardiovascular, renal and metabolic |
| Lutathera | 724 | 20 | 20 | Oncology |
| Exforge Group | 703 | -1 | 2 | Established brands |
| Scemblix | 689 | 67 | 68 | Oncology |
| Galvus Group | 602 | -13 | -6 | Established brands |
| Diovan Group | 590 | -4 | 0 | Established brands |